My bookmarksSign up free
Source

Commission Delegated Regulation (EU) 2022/519 of 14 January 2022 amending Delegated Regulation (EU) 2016/127 as regards the protein requirements for infant and follow-on formula manufactured from protein hydrolysates (Text with EEA relevance)

Commission Delegated Regulation (EU) 2022/519 of 14 January 2022 amending Delegated Regulation (EU) 2016/127 as regards the protein requirements for infant and follow-on formula manufactured from protein hydrolysates (Text with EEA relevance)

Delegated Regulation (EU) 2022/519 · Regulation · 3 articles

Data as of 2026-07-04 · Compiled from an official source version. Later amendments or repeals may not be reflected; the official text prevails. · Read the official text ↗

Article 1

Open ↗

Annexes I, II and III to Delegated Regulation (EU) 2016/127 are amended in accordance with the Annex to this Regulation.

Article 2

Open ↗

This Regulation shall enter into force on the day of its publication in the Official Journal of the European Union.

Supplementary provisions

ANNEXSupplementary provisions

Open ↗

ANNEX Annexes I, II and III to Delegated Regulation (EU) 2016/127 are amended as follows: (1) in Annex I, point 2.3 is replaced by the following: ‘2.3. Infant formula manufactured from protein hydrolysates Infant formula manufactured from protein hydrolysates shall comply either with the protein related requirements provided under point 2.3.1, or with the protein related requirements provided under point 2.3.2. 2.3.1. Protein related requirements group A 2.3.1.1. Protein content Minimum Maximum 0,44  g/100 kJ 0,67  g/100 kJ (1,86  g/100 kcal) (2,8  g/100 kcal) 2.3.1.2. Protein source Demineralised sweet whey protein derived from cows’ milk after enzymatic precipitation of caseins using chymosin, consisting of: (a) 63 % caseino-glycomacropeptide free whey protein isolate with a minimum protein content of 95 % of dry matter and protein denaturation of less than 70 % and a maximum ash content of 3 %; and (b) 37 % sweet whey protein concentrate with a minimum protein content of 87 % of dry matter and protein denaturation of less than 70 % and a maximum ash content of 3,5 %. 2.3.1.3. Protein processing Two-stage hydrolysis process using a trypsin preparation with a heat-treatment step (from 3 to 10 minutes at 80 to 100 °C) between the two hydrolysis steps. 2.3.1.4. Indispensable and conditionally indispensable amino acids and L-carnitine For an equal energy value, infant formula manufactured from protein hydrolysates must contain an available quantity of each indispensable and conditionally indispensable amino acid at least equal to that contained in the reference protein as set out in Section B of Annex III. Nevertheless, for calculation purposes, the concentration of methionine and cysteine may be added together if the methionine:cysteine ratio is not greater than 2, and the concentration of phenylalanine and tyrosine may be added together if the tyrosine:phenylalanine ratio is not greater than 2. The ratio of methionine:cysteine and of tyrosine:phenylalanine may be greater than 2, provided that the suitability of the product concerned for infants is demonstrated in accordance with Article 3(3). The L-carnitine content shall be at least equal to 0,3 mg/100 kJ (1,2 mg/100 kcal). 2.3.2. Protein related requirements group B 2.3.2.1. Protein content Minimum Maximum 0,55 g/100 kJ 0,67 g/100 kJ (2,3 g/100 kcal) (2,8 g/100 kcal) 2.3.2.2. Protein source Whey protein derived from cows’ milk, consisting of: (a) 77 % acid whey, coming from whey protein concentrate with a protein content of 35 to 80 %; (b) 23 % sweet whey, coming from demineralised sweet whey with a minimum protein content of 12,5 %. 2.3.2.3. Protein processing The source material is hydrated and heated. Following the heat-treatment step, the hydrolysis is carried out at a pH of 7,5 to 8,5 and a temperature of 55 to 70 °C with the use of an enzyme mixture of a serine endopeptidase and a protease/peptidase complex. The food enzymes are inactivated in a heat treatment step (from 2 to 10 seconds at 120 to 150 °C) during the production process. 2.3.2.4. Indispensable and conditionally indispensable amino acids and L-carnitine For an equal energy value, infant formula manufactured from protein hydrolysates must contain an available quantity of each indispensable and conditionally indispensable amino acid at least equal to that contained in the reference protein as set out in Section A of Annex III. Nevertheless, for calculation purposes, the concentration of methionine and cysteine may be added together if the methionine: cysteine ratio is not greater than 2, and the concentration of phenylalanine and tyrosine may be added together if the tyrosine:phenylalanine ratio is not greater than 2. The ratio of methionine:cysteine and of tyrosine:phenylalanine may be greater than 2, provided that the suitability of the product concerned for infants is demonstrated in accordance with Article 3(3). The L-carnitine content shall be at least equal to 0,3 mg/100 kJ (1,2 mg/100 kcal).’; (2) in Annex II point 2.3 is replaced by the following: ‘2.3. Follow-on formula manufactured from protein hydrolysates Follow-on formula manufactured from protein hydrolysates shall comply either with the protein related requirements provided under point 2.3.1, or with the protein related requirements provided under point 2.3.2. 2.3.1. Protein related requirements group A 2.3.1.1. Protein content Minimum Maximum 0,44  g/100 kJ 0,67  g/100 kJ (1,86  g/100 kcal) (2,8  g/100 kcal) 2.3.1.2. Protein source Demineralised sweet whey protein derived from cows’ milk after enzymatic precipitation of caseins using chymosin, consisting of: (a) 63 % caseino-glycomacropeptide free whey protein isolate with a minimum protein content of 95 % of dry matter and protein denaturation of less than 70 % and a maximum ash content of 3 %; and (b) 37 % sweet whey protein concentrate with a minimum protein content of 87 % of dry matter and protein denaturation of less than 70 % and a maximum ash content of 3,5 %. 2.3.1.3. Protein processing Two-stage hydrolysis process using a trypsin preparation with a heat-treatment step (from 3 to 10 minutes at 80 to 100 °C) between the two hydrolysis steps. 2.3.1.4. Indispensable and conditionally indispensable amino acids and L-carnitine For an equal energy value, follow-on formula manufactured from protein hydrolysates must contain an available quantity of each indispensable and conditionally indispensable amino acid at least equal to that contained in the reference protein as set out in Section B of Annex III. Nevertheless, for calculation purposes, the concentration of methionine and cysteine and the concentration of phenylalanine and tyrosine may be added together.` 2.3.2. Protein related requirements group B 2.3.2.1. Protein content Minimum Maximum 0,55 g/100 kJ 0,67 g/100 kJ (2,3 g/100 kcal) (2,8 g/100 kcal) 2.3.2.2. Protein source Whey protein derived from cows’ milk, consisting of: (a) 77 % acid whey, coming from whey protein concentrate with a protein content of 35 to 80 %; (b) 23 % sweet whey, coming from demineralised sweet whey with a minimum protein content of 12,5 %. 2.3.2.3. Protein processing The source material is hydrated and heated. Following the heat-treatment step, the hydrolysis is carried out at a pH of 7,5 to 8,5 and a temperature of 55 to 70 °C with the use of an enzyme mixture of a serine endopeptidase and a protease/peptidase complex. The food enzymes are inactivated in a heat treatment step (from 2 to 10 seconds at 120 to 150 °C) during the production process. 2.3.2.4. Indispensable and conditionally indispensable amino acids For an equal energy value, follow-on formula manufactured from protein hydrolysates must contain an available quantity of each indispensable and conditionally indispensable amino acid at least equal to that contained in the reference protein as set out in Section A of Annex III. Nevertheless, for calculation purposes, the concentration of methionine and cysteine and the concentration of phenylalanine and tyrosine may be added together.’; (3) Annex III is amended as follows: (a) Section A is amended as follows: (i) the title is replaced by the following: ‘Infant formula and follow-on formula manufactured from cows’ milk or goats’ milk proteins and infant formula and follow-on formula manufactured from soya protein isolates, alone or in a mixture with cows’ milk or goats’ milk proteins and infant formula and follow-on formula manufactured from protein hydrolysates’; (ii) the introductory sentence is replaced by the following: ‘For the purposes of points 2.1, 2.2 and 2.3.2 of Annexes I and II, the indispensable and conditionally indispensable amino acids in breast milk, expressed in mg per 100 kJ and 100 kcal, are the following:’; (b) in Section B, the introductory sentence is replaced by the following: ‘For the purposes of point 2.3.1 of Annexes I and II, the indispensable and conditionally indispensable amino acids in breast milk, expressed in mg per 100 kJ and 100 kcal, are the following:’.

Other acts of the same type
Commission Implementing Regulation (EU) 2026/2050 of 11 September 2026 granting a Union authorisation for the biocidal product family Hydrogen peroxide biocidal product family in accordance with Regulation (EU) No 528/2012 of the European Parliament and of the CouncilCommission Implementing Regulation (EU) 2026/2051 of 11 September 2026 granting a Union authorisation for the biocidal product family Hydrogen peroxide product family P & G in accordance with Regulation (EU) No 528/2012 of the European Parliament and of the CouncilCommission Implementing Regulation (EU) 2026/2054 of 11 September 2026 granting a Union authorisation for the biocidal product family Hydrogen peroxides biocides family in accordance with Regulation (EU) No 528/2012 of the European Parliament and of the CouncilCommission Implementing Regulation (EU) 2026/2094 of 11 September 2026 amending Annexes I and II to Implementing Regulation (EU) 2023/594 laying down special disease control measures for African swine feverCommission Implementing Regulation (EU) 2026/2022 of 10 September 2026 making imports of welded steel mesh originating in the People’s Republic of China and Türkiye subject to registration with a view to allowing the levy of anti-dumping duties on the imports subject to registrationCommission Implementing Regulation (EU) 2026/2023 of 10 September 2026 making imports of bolted and boltless steel shelves originating in the People’s Republic of China subject to registration with a view to allowing the levy of anti-dumping duties on the imports subject to registrationCommission Implementing Regulation (EU) 2026/2024 of 10 September 2026 amending Implementing Regulation (EU) 2024/2750 as regards administrative and minor changes to the Union authorisation of the biocidal product family LANXESS CMIT/MIT biocidal product familyCommission Implementing Regulation (EU) 2026/2025 of 10 September 2026 renewing the approval of the active substance mecoprop-P as a candidate for substitution in accordance with Regulation (EC) No 1107/2009 of the European Parliament and of the Council, and amending Commission Implementing Regulation (EU) No 540/2011Commission Implementing Regulation (EU) 2026/2026 of 10 September 2026 amending Implementing Regulation (EU) 2025/524 as regards administrative changes to the Union authorisation of the biocidal product family Sodium hypochlorite Liquid disinfectant biocidal product familyCommission Implementing Regulation (EU) 2026/2027 of 10 September 2026 concerning the authorisation of molybdenum chelate of EDTA as a feed additive for honeybees (holder of authorisation: Oligofeed SAS)Commission Implementing Regulation (EU) 2026/2028 of 10 September 2026 granting a Union authorisation for the single biocidal product ELOCLEAR in accordance with Regulation (EU) No 528/2012 of the European Parliament and of the CouncilCommission Implementing Regulation (EU) 2026/2053 of 10 September 2026 granting a Union authorisation for the biocidal product family Glutaraldehyde formulations in accordance with Regulation (EU) No 528/2012 of the European Parliament and of the Council

Source: EUR-Lex (Publications Office of the EU), © European Union, reuse permitted under Commission Decision 2011/833/EU.

Contents

What to look at next